Press release 18 August, 2009

Orexo announces that its partner Meda has initiated the launch of Edluar™ in the USA

Uppsala, Sweden, 18 August 2009 - Orexo (STO: ORX) confirms that Meda (STO: MEDA A) has initiated the launch the drug Edluar™ in the United States of America. The launch follows the US Food and Drug Administration's (FDA) approval in March this year of Edluar™ 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

Meda acquired exclusive worldwide commercialization rights for Edluar™ from Orexo in 2008. Orexo will receive royalty payments on Meda's sales of Edluar™ in the USA.

Commenting on the news, Torbjörn Bjerke, CEO of Orexo said: "Edluar™ offers insomnia sufferers a convenient and effective treatment and Meda is well placed to sell Edluar™ in the US market."

Edluar™ is a fast-acting, sublingual formulation of the well-known substance zolpidem. It is based on Orexo's sublingual technology, involving a tablet placed under the tongue for fast and effective absorption of the active ingredient across the oral mucosa.

For more information, please contact:
Torbjörn Bjerke, President and CEO, Orexo
Tel: +46 (0)708-66 19 90
E-mail: torbjorn.bjerke@orexo.com

Johan Andersson, Investor Relations Manager, Orexo
Tel: +46 (o) 702-10 04 51
E-mail: johan.andersson@orexo.com

About Orexo

Orexo is a pharmaceutical company focused on developing drugs for the treatment of pain and inflammation. The company has four products on the market as well as a competitive project portfolio in late stages of development. Sales and product development are mainly carried out through worldwide partnership agreements with larger pharmaceutical companies. Orexo has 128 employees, and has its head office located in Uppsala, Sweden. More information could be found at www.orexo.com.

Note:
This is information that Orexo AB (publ) is required to disclose pursuant to the Swedish Securities Markets Act. The information was provided for public release on August 18, 2009 at 08:00 CET.

WEB www.orexo.com
E-MAIL info@orexo.com
POST Orexo AB, BOX 303, SE-751 05 Uppsala, Sweden
PHONE +46 (0)18 780 88 00
FAX +46 (0)18 780 88 88 Uppsala, +46 (0)18 780 89 99 Solna
CORP. REG. NO. 556500-0600